{"filings":[{"id":92555,"accession_number":"0001386570-26-000031","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.","Launched clinician-directed telehealth platform Niagen Plus and first cruise ship clinic partnership.","Completed divestiture of Analytical Reference Standards segment to LGC Standards in Feb 2026.","Board approved $20M share repurchase program; repurchased $2.4M in Q1.","FY 2026 G&A outlook improved to +$3-4M vs prior +$4-5M; sales & marketing investment to rise."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":31474000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103477,"accession_number":"0001386570-26-000017","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Niagen Bioscience increases share repurchase authorization to $20M from $10M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved increase of share repurchase program from $10M to $20M.","Approximately $2.6M of common stock repurchased through March 17, 2026.","Program runs through October 31, 2027, unless modified or terminated.","CEO Rob Fried cited conviction in strategy and long-term value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103476,"accession_number":"0001386570-26-000014","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience reports 30% net sales growth to $129.4M in 2025; net income up 103% to $17.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 net sales $129.4M (+30% YoY); net income $17.4M (+103%); adjusted EBITDA $20.4M (+139%).","Q4 net sales $33.8M (+16% YoY); Q4 net income $4.1M vs $7.2M prior; Q4 adjusted EBITDA $4.1M (+$0.7M).","Gross margin improved 250 bps to 64.3% for year; cash $64.8M at Dec 31, 2025.","FY 2026 net sales outlook 10-15% growth ex. reference standards segment sold in Feb 2026 for ~$6M.","Acquired foundational NR patent portfolio from Queen’s University Belfast (Dec 2025); launched Tru Niagen Beauty (Nov 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103475,"accession_number":"0001386570-26-000003","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Niagen Bioscience sells ChromaDex Reference Standards business to LGC in all-cash deal","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["All-cash sale closed Feb 24, 2026; buyer is VHG Labs, part of LGC Group.","Divestiture exits non-core activities; focuses on NAD+ science, IP, commercial growth.","Transition services agreement for up to 6 months; service fee recognized as performed.","No purchase price or financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119726,"accession_number":"0001386570-25-000030","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Niagen acquires QUB NR patent portfolio; $1M upfront, annual payments through 2038","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["One-time ~$1M payment to QUB for accrued royalties through 2024; annual $500K+£35K through 2038.","Additional one-time payments of $1.5M in 2035 and $2M in 2038 as consideration for patent assignment and release.","QUB assigned all patent rights to ChromaDex; prior JOMA and License Agreement terminated with royalty obligations released.","Acquired portfolio includes composition-of-matter patents for NR salt forms (e.g., NR Malate, NR Tartrate) and global rights.","Niagen now sole owner of core NR IP estate with >90 patents worldwide; CEO cites enhanced control and shareholder protection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119725,"accession_number":"0001386570-25-000025","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Niagen Bioscience authorizes $10M share repurchase program through October 2027","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board authorized up to $10M in common stock repurchases over ~2 years; expires Oct 31, 2027.","Repurchases may occur in open market or private negotiations; no obligation to buy any shares.","CEO Rob Fried states company is \"an excellent investment\" and program is compelling use of capital.","Program may be modified, suspended, or terminated at any time at Board's discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119724,"accession_number":"0001386570-25-000021","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q3 net sales up 33% to $34M, net income $4.6M, raises FY sales growth outlook to 25-30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $34.0M (+33% YoY); Tru Niagen sales $26.0M (+44% YoY).","Net income $4.6M ($0.06 EPS) vs $1.9M ($0.02 EPS) prior year; adjusted EBITDA $6.4M (+120%).","Gross margin 64.5% (+100 bps); sales & marketing expense as % of sales improved 170 bps to 25.8%.","New FY 2025 outlook: net sales growth 25-30% (from 22-27%); reaffirms momentum in Tru Niagen and Niagen ingredients.","Operational: launched AboutNAD platform, won NAD+ advertising challenge, expanded clinic network to 1,000+ sites."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":95584000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119723,"accession_number":"0001386570-25-000015","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Niagen Bioscience raises FY2025 net sales growth guidance to 25%-30% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 net sales outlook raised to 25%-30% YoY growth from prior 22%-27%.","CEO cites FDA reversal on DSHEA drug preclusion rule for NMN as potential awareness driver.","Press release notes every NMN supplement tested infringes on Niagen's patent portfolio.","Niagen (patented NR) claims superior bioavailability vs. NMN, with three in four NMN products failing label claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136302,"accession_number":"0001386570-25-000011","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q2 net sales up 37% to $31.1M; raises FY2025 guidance to 22%-27% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $31.1M (+37% YoY); net income $3.6M ($0.05 EPS) vs breakeven in Q2 2024.","Gross margin improved 480 bps to 65.0%; adjusted EBITDA $5.0M, up 221%.","Raises FY2025 revenue growth outlook to 22%-27% (previously 20%-25%).","Secured exclusive worldwide license for Niagen in Parkinson's therapy; NOPARK Phase III trial dosing completed, data expected 2026.","Niagen Plus available in 800+ U.S. wellness clinics (up from 475 in Dec 2024); cash $60.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":61598000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136301,"accession_number":"0001628280-25-036445","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Niagen subsidiary ChromaDex signs exclusive NRCL supply deal with W.R. Grace through 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive supply of Nicotinamide-beta-Riboside Chloride (NRCL); Grace cannot sell to third parties.","Initial term through April 30, 2029, with automatic 12-month renewals unless 90-day non-renewal notice.","ChromaDex must purchase minimum annual quantities and provide rolling 24-month forecasts with first 12 months binding.","Parties will negotiate a royalty-bearing license to Grace's NRCL manufacturing patents upon termination under specified conditions.","2025 product price set at $[***]/kg; each party may propose up to 5% price adjustment twice per year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153419,"accession_number":"0001628280-25-033302","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve 4.75M share increase to equity plan and new ESPP at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to 2017 Equity Incentive Plan adds 4,750,000 shares; approved by 53,046,229 votes for.","Employee Stock Purchase Plan approved: 650,000 shares authorized, purchased at 85% of lower of grant/ purchase price.","All eight director nominees elected; Steven Rubin received 12.4M withheld votes, others largely unanimous.","Crowe LLP ratified as independent auditor for FY2025 with 63.4M votes for.","Advisory say-on-pay proposal passed with 54.9M for vs 1.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153418,"accession_number":"0001628280-25-023129","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).","Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.","Adjusted EBITDA of $4.9M, up from $0.7M in prior year.","Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.","Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":30481000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172167,"accession_number":"0001628280-25-013681","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"ChromaDex rebrands as Niagen Bioscience; Nasdaq ticker becomes NAGE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change from ChromaDex Corporation to Niagen Bioscience, Inc. effective March 19, 2025.","Common stock begins trading under new ticker symbol 'NAGE' on Nasdaq; CUSIP unchanged.","Rebranding reflects focus on flagship Niagen ingredient and NAD+ healthy-aging science; no operational changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172166,"accession_number":"0001628280-25-009785","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex reports record Q4 net sales $29.1M (+37% YoY); first full-year net income $8.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year net sales $99.6M (+19% YoY); Tru Niagen sales $76.8M (+10%), Niagen ingredients $19.2M (+82%).","Q4 net income $7.2M vs $0.1M a year ago; full-year net income $8.6M vs net loss $4.9M in 2023.","Adjusted EBITDA $8.5M in 2024; operating cash flow $12.1M; cash $44.7M with no debt.","G&A expense dropped $6.6M for the year due to $3.5M royalty reversal and $1.3M legal settlement recovery.","FDA granted Orphan Drug and Rare Pediatric Disease Designations for NR; Niagen Plus now at 475+ clinics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172165,"accession_number":"0001628280-25-008691","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex amends CEO Fried's contract to $650k base, grants 1.5M PSUs with $15-$50 stock price targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary increased to $650,000 effective Jan 1, 2025; target bonus raised to 75% of base for FY2025.","CEO granted 1,518,600 PSUs with 7-year performance period; vest at stock price thresholds of $15, $20, $30, $40, $50.","First tranche (759,300 PSUs) vests at $15 VWAP for 60 trading days; subsequent 189,825 each at higher thresholds.","PSUs subject to five-year transfer restriction after vesting; no cash-out feature; forfeiture if targets not met by 2032.","Under termination without cause or for good reason, unvested PSUs remain eligible for 12 months; transfer restrictions lapse."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189142,"accession_number":"0001628280-24-051374","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"ChromaDex appoints Crowe LLP as new independent auditor effective December 13, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee approved Crowe LLP as independent auditor for fiscal year ending Dec 31, 2024, effective Dec 13, 2024.","No disagreements with prior auditor during fiscal years 2023 and 2022 and subsequent interim period.","No consultations with Crowe regarding application of accounting principles or audit opinion prior to engagement.","Change follows competitive request-for-proposal process conducted by Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189141,"accession_number":"0001628280-24-049951","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ChromaDex obtains waiver of ~$3.5M in accrued royalties from Dartmouth contingent on appeal bond in Elysium case","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dartmouth waives ~$3.5M in accrued unpaid royalties, license fees, and maintenance expenses under exclusive license agreements.","Waiver contingent on ChromaDex securing an Appeal Bond for fee judgment in Delaware patent infringement case against Elysium Health.","ChromaDex executed the Appeal Bond as of December 3, 2024; plans to move to stay execution of fee judgment pending appeal.","No further royalties or payments will be owed to Dartmouth for the licensed patents after effective date of Supplemental Agreement.","Supplemental Agreement supplements prior exclusive license agreements from 2012 and 2014 for Dartmouth-owned U.S. patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189140,"accession_number":"0001628280-24-048830","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.","Roth Capital Partners added as Sales Agent; B. Riley Securities removed.","Raymond James & Associates and Roth Capital Partners remain as the two Sales Agents.","No changes to the $0.001 par value common stock or ATM program terms beyond agent roster.","Agreement governs at-the-market equity offering program for ChromaDex common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189139,"accession_number":"0001628280-24-044541","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex posts record Q3: net sales $25.6M (+31% YoY), net income $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $25.6M (+31% YoY); gross margin 63.5% (+210 bps).","Net income $1.9M ($0.02 EPS) vs net loss $1.0M ($0.01 loss) in Q3 2023.","Record Adjusted EBITDA $2.9M, up from $0.5M YoY; operating cash $32.4M.","Niagen ingredient sales $6.7M (+368% YoY); Tru Niagen sales $18.1M (+4% YoY).","Expanded Niagen+ to >100 wellness clinics; pursuing FDA IND for Ataxia Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":70472000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189138,"accession_number":"0001628280-24-042724","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ChromaDex auditor Marcum resigns effective Oct 31 due to conflict from CBIZ merger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as independent auditor effective Oct 31, 2024, citing independence concerns from its impending merger with CBIZ Inc.","CBIZ provides HR consulting and health insurance brokerage services to ChromaDex, creating a conflict under independence rules.","Marcum's audit reports for fiscal years 2022 and 2023 contained no adverse opinions or qualifications.","No disagreements or reportable events occurred during the relevant periods; Board and Audit Committee were not involved in the resignation decision.","Company has not yet named a replacement auditor; Marcum's letter to SEC filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205630,"accession_number":"0001628280-24-040982","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex appoints Ozan Pamir as CFO effective October 21, 2024; James Lee returns to Controller role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ozan Pamir named CFO effective Oct 21; succeeds interim CFO James Lee who remains Controller.","Annual base salary of $400,000; target bonus 50% of base; option grant with initial value of $360,000.","Pamir previously CFO of 180 Life Sciences; also held investment banking roles at Ventum Financial.","Option vests: 1/3 one-year anniversary, rest over 24 months; severance: 9 months' base salary on termination without cause."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205629,"accession_number":"0001628280-24-035593","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q2 net sales up 12% to $22.7M; adjusted EBITDA positive $1.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net sales $22.7M (+12% YoY); Tru Niagen sales $18.6M (+10% YoY).","Gross margin 60.2%; operating expenses down $0.7M YoY to $13.9M.","Net loss approximately breakeven, a $2.2M improvement vs Q2 2023 loss of $2.2M.","Adjusted EBITDA improved to $1.6M from $0.2M in prior year quarter.","FDA Orphan Drug and Rare Pediatric Disease Designation for nicotinamide riboside chloride in Ataxia Telangiectasia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":44892000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205628,"accession_number":"0001628280-24-031955","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ChromaDex appoints James Lee as Interim CFO after Brianna Gerber resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brianna Gerber resigned as CFO and Principal Accounting Officer effective July 12, 2024.","James Lee, Controller since 2009, appointed Interim CFO and Interim Principal Accounting Officer effective July 13, 2024.","Gerber will consult on financial and accounting matters through August 12, 2024 under prior agreement.","Lee holds B.A. in Architecture from UC Berkeley and MBA from UIUC; previously accounting manager at Samsung."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222570,"accession_number":"0001628280-24-029936","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ChromaDex CFO Brianna Gerber resigns effective July 12; consulting transition through Aug 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO & CAO Brianna Gerber resigns effective July 12, 2024; company beginning search for replacement.","Post-resignation consulting agreement through Aug 12, 2024; $1,000 consulting fee.","Outstanding stock options and RSUs continue to vest during consulting period per existing equity plan terms.","Gerber confirms resignation is without Good Reason; no severance benefits under employment agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222569,"accession_number":"0001628280-24-029643","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ChromaDex shareholders elect all 8 director nominees, ratify auditor, and approve say-on-pay at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected: Jaksch, Fried, Rubin, Yu, Ng, Patrick, Cohen, Shahbazi.","Ratification of Marcum LLP as FY 2024 auditor passed with 49.6M for, 3.4M against, 83,650 abstain.","Advisory approval of named executive officer compensation passed with 40.8M for, 0.9M against, 0.5M abstain.","Broker non-votes of 10.9M reported for director election and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222568,"accession_number":"0001628280-24-021648","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex Q1 net sales $22.2M, net loss narrows to $0.5M; reiterates 16%+ FY growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $22.2M (-2% YoY); Tru Niagen sales $17.4M. Gross margin 60.7% (+80 bps).","Net loss $0.5M ($0.01 loss per share), improved from $1.9M loss in Q1 2023.","Adjusted EBITDA positive $0.7M vs -$0.1M prior year; cash $27.6M, no debt.","Full-year 2024 outlook reiterated: net sales growth of at least 16%.","Tru Niagen expanded to 700 Vitamin Shoppe stores and 400 Sprouts Farmers Market locations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":22153000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242082,"accession_number":"0001628280-24-009383","cik":1386570,"company_name":"Niagen Bioscience, Inc.","ticker":"NAGE","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ChromaDex posts Q4 net income of $0.1M; FY2023 revenue up 16% to $83.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $21.2M (+1% YoY); Tru Niagen sales $17.6M (+9% YoY).","Q4 gross margin 61.0% (up 380 bps); net income $0.1M vs loss of $1.4M prior year.","Full-year net loss improved $11.6M to $4.9M; positive Adjusted EBITDA of $1.9M.","Cash $27.3M, no debt; positive operating cash flow for fourth consecutive quarter.","Exceeded FY2023 outlook for gross margin and G&A; expects accelerated growth in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":313400413.99477804,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}